FDA continues to construct its regulatory program for cosmetic products, albeit at a slower pace than the congressional timelines provided in the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). FDA has yet to provide explanatory guidance on several congressionally mandated items including fragrance allergen disclosures, product safety substantiation, and serious adverse event reporting. FDA’s Fall 2024 Unified Agenda published on December 15 provided some updated timelines ranging...
By:
By: